Neuroventis

Neuroventis operates at the intersection of digital health, neurology, and regulated medical-device software. Its differentiation is its narrow clinical focus: rather than offering a general wellness tracker, the company combines patient-reported information, sensor inputs, behavioral science, and data engineering for neurological conditions. The Neuroventis Platform is described as a CE-marked medical device intended to help patients register and manage neurological disorders while sharing information with their medical teams. Helpilepsy and MigraineManager extend that model into epilepsy and headache care, supported by a healthcare dashboard for professionals. Relative to broad patient-monitoring or symptom-tracking products, Neuroventis appears more specialized in neurology and more focused on clinician collaboration and treatment support. Its approximately $1.19 million disclosed funding total and estimated 11–50 employee range indicate an early-stage scale, with commercialization and regulatory execution likely more relevant market factors than financial scale alone.

Neuroventis was founded in 2017 and has developed from a neurology-focused digital health concept into a portfolio comprising the Neuroventis Platform, Helpilepsy, and MigraineManager. The clearest financing inflection point was the $1 million seed round announced on Mar 16, 2021, backed by CAREvolution, PMV, imec.istart, and BlueHealth Innovation Center. A subsequent non-equity assistance event involving PharmStars was recorded on Jul 12, 2022, but no amount was disclosed. The company’s products have reached mobile distribution, with the latest available activity metrics showing 1,875 monthly Google Play downloads for one Helpilepsy listing and 239 combined Google Play and iTunes monthly downloads for MigraineManager at the time measured. Neuroventis has historically advertised roles in Brussels and Germany, including quality and regulatory work, suggesting attention to operational scaling and medical-device compliance. The trajectory therefore supports measured product development, but not a conclusion of rapid expansion.